# Law Debenture investment trust increases AstraZeneca and GSK holdings | October factsheet

- Link: https://www.directorstalkinterviews.com/law-debenture-investment-trust-increases-astrazeneca-and-gsk-holdings-october-factsheet/4121269829
- Published: 2026-11-16T07:07:00+00:00
- Author: Amilia Stone

**[Law Debenture](https://www.directorstalkinterviews.com/company/law-debenture-corporation-plc/lwdb.l)
Corporation plc **(LON:LWDB) has announced its fact sheet as at 30th October 2026:

**Fund Managers’ Comments**

In October the Trust’s NAV fell 0.6%, underperforming the FTSE All-Share benchmark
which rose 1.1%. In a backdrop where the oil price rose and the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of AI capital expenditure was being questioned, there was a sharp rotation in markets
with defensive sectors outperforming. Oil producers such as Shell and BP performed
well (both share prices rose 13-14% in October), as did data services companies 
Relx and LSEG (where the share prices rose 20% and 16% respectively). While Relx
and LSEG had been seen as at risk of AI disintermediation earlier in the year, a
further set of encouraging quarterly results led to a sharp relief rally. In contrast,
cyclical sectors such as industrials performed poorly, as investors questioned whether
rising input costs and a potential slowdown in AI capex would suppress future earnings
growth. Industrial holdings such as Hill & Smith therefore performed poorly. Aside
from industrials, the key detractors
from the portfolio compared to its FTSE All-
Share benchmark were holding less in large index weights that performed well, such
as Shell and AstraZeneca, and holding more in AI-exposed next generation energy 
companies, for example fuel cell developer Ceres Power. We had taken substantial
profits in Ceres earlier this calendar year, and the position size is now modest
at less than 1%.

From a transactions perspective, within the healthcare sector we sold the positions
in Swiss pharmaceutical Roche and US medical devices company Becton Dickinson following
good performance. The proceeds were partially rotated into AstraZeneca and GSK. 
In the case of AstraZeneca, following the initial purchase last month we have continued
to gradually add to the holding, while in the case of GSK we added on what we saw
as an overreaction to a largely in line set of
quarterly results.

James Henderson and Laura Foll
Janus Henderson

[LWDB](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/LWDB.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/LWDB.pdf)

Share on:
